Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Akebia Therapeutics (AKBA) Stock Price & Analysis
1,217 Followers
AKBA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.78 - $2.48
Previous Close$1.33
Volume977.21K
Average Volume (3M)5.15M
Market Cap
$251.51M
Enterprise Value$279.47M
Total Cash (Recent Filing)$42.92M
Total Debt (Recent Filing)$43.63M
Price to Earnings (P/E)-6.0
Beta1.17
Next Earnings
Aug 01, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding209,372,275
10 Day Avg. Volume3,532,252
30 Day Avg. Volume5,151,895
Standard Deviation0.31
R-Squared0.03
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-2.33
Price to Sales (P/S)1.43
Price to Cash Flow (P/CF)-31.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.55
Enterprise Value/Gross Profit2.32
Enterprise Value/Ebitda-38.87
Forecast
1Y Price Target
$5.00Price Target Upside316.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Akebia Therapeutics News
PremiumCompany Announcements
Akebia Therapeutics Celebrates FDA Approval of Anemia DrugBulls Say, Bears Say
Bulls Say
Competitive AdvantageThe Vafseo label includes a simple dosing regimen and does not carry a warning for 'risk of hospitalization for heart failure' unlike its competitor, providing a potential advantage.
Financial HealthCompany has sufficient cash runway to fund operations for 24 months, ensuring stability while awaiting vadadustat's approval.
Regulatory ApprovalFDA approves Vafseo for anemia in CKD on dialysis, marking a significant regulatory milestone.
Bears Say
Drug Safety PerceptionVafseo's label comes with black box warnings, which are standard for drugs in its class but may affect its perception among prescribers and patients.
Financial StabilityAkebia must maintain a cash balance of at least $15M or achieve total revenue over $150M to meet the key financial covenant of the loan.
Regulatory ApprovalRisks include potential failure to secure FDA approval for vadadustat in dialysis.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.78 and its highest was $2.48 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Currently, no data Available
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 83 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on May 09, 2024. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.072 by -$0.018.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 209,595,260 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.072. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Among the largest hedge funds holding Akebia Therapeutics’s share is Graham Capital Management, L.P.. It holds Akebia Therapeutics’s shares valued at 29K.
---
Akebia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (316.67% Upside)
$5.00 (316.67% Upside)
Blogger Sentiment
Bullish
AKBA Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 23.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $212.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.56%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
---
AKBA Earnings Call
Q1 2024
0:00 / 0:00
---
AKBA Stock 12 Month Forecast
Average Price Target
$5.00
▲(316.67% Upside)
Technical Analysis
Best Analysts Covering AKBA
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-24.52%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -24.52% per trade.
---